Advertisement

Topics

Bavarian Nordic and Janssen to develop vaccines against HIV-1 and hepatitis B

19:00 EDT 30 Jul 2017 | Pharmaceutical Technology

Danish biotechnology company Bavarian Nordic has entered an additional worldwide exclusive licence and collaboration agreement with Janssen Pharmaceuticals for the development of vaccine regimens against HIV-1 and hepatitis B.

Original Article: Bavarian Nordic and Janssen to develop vaccines against HIV-1 and hepatitis B

NEXT ARTICLE

More From BioPortfolio on "Bavarian Nordic and Janssen to develop vaccines against HIV-1 and hepatitis B"

Quick Search
Advertisement
 

Relevant Topics

Biotechnology
Antibodies Antisense Assays Biochips Bioinformatics Biological Therapy Biomarkers Biomaterials Bioscience Cell Culture Cloning Cytokine Diagnostics Dna Extraction Dna Sequencing Dna Transform...

Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...

Mergers & Acquisitions
Commercial and market reports on mergers and acquisitions in the biotechnology, pharmaceutical, medical device and life-science industries. Mergers and acquisitions (abbreviated M&A;) is an aspect of corporate strategy, corporate finance and manageme...